Daniel P Cahill MD PhD
Brain & Spinal Tumor
Associate Professor, Neurosurgery-Massachusetts General Hospital, Harvard Medical School
Join to View Full Profile
55 Fruit StMassachusetts General Hospital Nsurg HSTBoston, MA 02114
Phone+1 617-726-2066
Fax+1 617-726-4814
Dr. Cahill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Daniel Cahill is a neurosurgeon in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 16 years. He specializes in brain & spinal tumor and is experienced in neurosurgical oncology, including primary brain tumors (IDH mutant glioma, astrocytoma, oligodendroglioma, and glioblastoma), metastatic brain tumors (including melanoma, lung cancer, breast cancer), and meningioma.
Education & Training
Mass General Brigham/Massachusetts General HospitalResidency, Neurological Surgery, 2001 - 2008- Massachusetts General HospitalInternship, Transitional Year, 2001 - 2002
Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2004 - 2026
TX State Medical License 2008 - 2017
American Board of Neurological Surgery Neurological Surgery
Publications & Presentations
PubMed
- Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors.Tyler A Lanman, Hana Gross, Caylin M Faria, Julie J Miller, Daniel P Cahill
Journal of Neuro-Oncology. 2025-11-01 - Associations of supramaximal resection with outcome in glioblastoma across age groups: a report of the RANO resect group.Nico Teske, Antonio Dono, Jacob S Young, Stephanie T Juenger, Gilbert C Youssef
Neuro-Oncology. 2025-10-25 - Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Aleksandra B Lasica, Zhou Lan, Julie J Miller, Albert Jiao, Ian Pan
Neuro-Oncology. 2025-10-14
Journal Articles
- The Dual PI3K/mTOR-pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain MetastasesPriscilla K Brastianos, Daniel P Cahill, Clinical Cancer Research
- DMD Genomic Deletions Characterize a Subset of progressive/higher-grade Meningiomas with Poor OutcomeGanesh M Shankar, Sandro Santagata, Priscilla K Brastianos, Daniel P Cahill, Acta Neuropathologica
- Cell Surface Notch Ligand DLL3 Is a Therapeutic Target in Isocitrate Dehydrogenase Mutant GliomaJohn G Golfinos, Daniel P Cahill, Erik P Sulman, David Zagzag, Clinical Cancer Research
Press Mentions
New Targeted Glioma Therapy Could Suppress Tumor GrowthAugust 9th, 2018
Rapid Diagnostic Coupled with Local Therapy Developed for Brain TumorsAugust 6th, 2018- Molecular Approach to Brain Tumors Improves TreatmentFebruary 10th, 2016
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
